At Shorla Oncology we develop and commercialize innovative oncology drugs for women’s and pediatric cancers. We focus on indications where existing treatments are limited, in shortage or inadequate for the target population. Our products are the result of Shorla’s world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments.Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.

Enterprise Ireland

Seroba Life Sciences

Shorla Oncology

Incyte is a pharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.

Incyte

Syndax is a clinical-stage biopharmaceutical company focused on developing therapies for various cancer indications.

Syndax

Immunocore is a biotechnology company specializing in the development of novel T cell receptor-based immunotherapies for cancer.

Immunocore

Fog Pharmaceuticals is a biopharmaceutical company dedicated to developing novel therapeutics for cancer and other diseases.

Fog Pharmaceuticals

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapies for rare diseases and cancer.

Mereo BioPharma

Blueprint Medicines is a precision therapy company focused on developing targeted therapies for cancer and rare diseases.

Blueprint Medicines

Shorla Oncology is a pharmaceutical company focused on developing innovative oncology products to address unmet clinical needs. The company aims to improve patient care by providing therapies that are easier to administer and have the potential to reduce side effects.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 11, 2024 7:43 AM	62f627fe
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 11, 2024 3:32 PM	6ca4b6c7
company summary	general
signals	general
crunchbase trigger	general	Nov 12, 2024 12:52 PM	b60be86d
crunchbase profile	general
li profile	general	May 11, 2024 7:43 AM	c27f48cb
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 11, 2024 7:43 AM	fca2a251
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:SHORLAONCOLOGY

Shorla Oncology